Literature DB >> 8136518

The costs of health care: implications for anti-emetic therapy.

N Bosanquet1.   

Abstract

Health economists assess new drug innovations to improve choice. Decision-making techniques for cost analysis should include not only direct costs but costs in terms of increased health benefit, reduced mortality and improved quality of life. The use of anti-emetic drugs results in a significant improvement in the quality of life of patients and decision making on the use of anti-emetic drugs should fully evaluate this patient benefit.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8136518     DOI: 10.1097/00001813-199312003-00003

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

Review 1.  Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.

Authors:  G L Plosker; P Benfield
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

Review 2.  Costs and benefits of antiemetic therapy.

Authors:  M S Aapro
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.